Mehrdad Abedi, MD, discusses Orca-T, a high precision cell therapy, for patients with acute and chronic graft-vs-host disease.
Mehrdad Abedi, MD, a professor of cancer, hematology/oncology, and internal medicine in the Department of Internal Medicine, Division of Hematology and Oncology at the UC Davis Comprehensive Cancer Center, discusses Orca-T, a high precision cell therapy, for patients with acute and chronic graft-vs-host disease (GVHD).
Orca Bio approached UC Davis a few years ago to start collaborative research with the Good Manufacturing Practice facility and produce these products. Each graft of the Orca-T product has stem cells and immune cells in it. The stem cells are needed to maintain the graft and allow the product to stay in the patient for a long time, according to Abedi. The immune cells cause graft-vs-leukemia effects, which is what they want.
Abedi says it is clear that there is a population of T cells called T-regulatory cells that can prevent GVHD as seen in work from multiple investigators. There are other populations, such as the naïve T cells or conventional T cells, that can cause GVHD. A smaller number of those cell may be helpful; they can cause graft-vs-leukemia, but not GVHD.
The graft is designed so that the investigators can give stem cells, but they remove a lot of conventional T cells that can cause GVHD. The graft provides a small amount of conventional T cells that can cause graft-vs-leukemia effects, as well as the regulatory T cells that can prevent GVHD, Abedi explains.
Lachowiez Considers the Use of Tagraxofusp in BPDCN as Bridge to SCT With Peers
March 21st 2024During a Targeted Oncology™ Case-Based Roundtable™ event, Curtis Lachowiez, MD, discussed targeted therapy for blastic plasmacytoid dendritic cell neoplasm and its role in patients who could receive allogeneic stem cell transplant.
Read More
Behind the FDA Approval of Liso-cel for Relapsed/Refractory CLL/SLL
March 15th 2024In an interview with Targeted Oncology, Tanya Siddiqi, MD, discussed the rationale behind the TRANSCEND CLL 004 study supporting the FDA approval of lisocabtagene maraleucel in chronic lymphocytic leukemia or small lymphocytic lymphoma.
Read More